AR072781A1 - COMPOSITIONS THAT INCLUDE CDB-4124 AND MALE CONTRACEPTION METHODS - Google Patents

COMPOSITIONS THAT INCLUDE CDB-4124 AND MALE CONTRACEPTION METHODS

Info

Publication number
AR072781A1
AR072781A1 ARP090101511A ARP090101511A AR072781A1 AR 072781 A1 AR072781 A1 AR 072781A1 AR P090101511 A ARP090101511 A AR P090101511A AR P090101511 A ARP090101511 A AR P090101511A AR 072781 A1 AR072781 A1 AR 072781A1
Authority
AR
Argentina
Prior art keywords
man
methyl
compound
cdb
compositions
Prior art date
Application number
ARP090101511A
Other languages
Spanish (es)
Inventor
Ronald D Wiehle
Joseph S Podolski
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of AR072781A1 publication Critical patent/AR072781A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Un método para inhibir la espermatogénesis en un hombre, caracterizado porque comprende administrarle a dicho hombre un agonista del receptor de androgenos y una composicion que comprende un compuesto de la formula (1), o una sal aceptable para uso farmacéutico, hidrato o solvato del mismo, en donde: X representa un alquilo, alquenilo, alquinilo, hidrogeno, halo, monoalquilamino o dialquilamino; R1 representa O, NOH o NO-metilo; R2 representa un hidrogeno o acetilo; y R3 representa metiloxi, formiloxi, acetoxi, acetilteonilo, glicimato, viniléter, acetiloximetilo, carbonato de metilo, halogenos, metilo, hidroxi o etiloxi; con lo cual se inhibe la espermatogénesis en dicho hombre. Reivindicacion 4: El método de la reivindicacion 1, caracterizado porque dicho compuesto es CDB-4124. Reivindicacion 8: El método de la reivindicacion 1, caracterizado porque además comprende la administracion de al menos un compuesto seleccionado del grupo que consiste de una progestina, un agonista de la hormona de liberacion de gonadotrofina (GnRH) y un antagonista de GnRH. Reivindicacion 9: El método de la reivindicacion 1, caracterizado porque la composicion se administra por un período de tiempo eficaz para prevenir la concepcion.Claim 1: A method for inhibiting spermatogenesis in a man, characterized in that it comprises administering to said man an androgen receptor agonist and a composition comprising a compound of the formula (1), or a salt acceptable for pharmaceutical, hydrate or solvate thereof, wherein: X represents an alkyl, alkenyl, alkynyl, hydrogen, halo, monoalkylamino or dialkylamino; R1 represents O, NOH or NO-methyl; R2 represents a hydrogen or acetyl; and R3 represents methyloxy, formyloxy, acetoxy, acetylteonyl, glycyate, vinyl ether, acetyloxymethyl, methyl carbonate, halogens, methyl, hydroxy or ethyloxy; whereby spermatogenesis is inhibited in said man. Claim 4: The method of claim 1, characterized in that said compound is CDB-4124. Claim 8: The method of claim 1, characterized in that it further comprises the administration of at least one compound selected from the group consisting of a progestin, a gonadotrophin release hormone (GnRH) agonist and a GnRH antagonist. Claim 9: The method of claim 1, characterized in that the composition is administered for an effective period of time to prevent conception.

ARP090101511A 2008-04-28 2009-04-28 COMPOSITIONS THAT INCLUDE CDB-4124 AND MALE CONTRACEPTION METHODS AR072781A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4844408P 2008-04-28 2008-04-28

Publications (1)

Publication Number Publication Date
AR072781A1 true AR072781A1 (en) 2010-09-22

Family

ID=40756947

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101511A AR072781A1 (en) 2008-04-28 2009-04-28 COMPOSITIONS THAT INCLUDE CDB-4124 AND MALE CONTRACEPTION METHODS

Country Status (4)

Country Link
AR (1) AR072781A1 (en)
CL (1) CL2009001009A1 (en)
TW (1) TW200950788A (en)
WO (1) WO2009134713A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054197A1 (en) * 2014-09-30 2016-04-07 University Of Tennessee Research Foundation In situ gelling form for long-acting drug delivery

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007103510A2 (en) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders

Also Published As

Publication number Publication date
CL2009001009A1 (en) 2009-06-19
TW200950788A (en) 2009-12-16
WO2009134713A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
AR117670A2 (en) ANDROGEN RECEPTOR MODULATOR AND ITS USES
WO2013016697A3 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
ECSP034654A (en) STEROID HORMONE PRODUCTS AND METHODS TO PREPARE THE SAME
BRPI0512993A (en) use of a pr antagonist, pharmaceutically useful kit, and method of contraception in a female of childbirth
PE20060275A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PROGESTIN AND ESTROGEN FOR THE TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER
CO5271697A1 (en) COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF AFFECTIONS THAT RESPOND TO AN INCREASE OF TESTOSTERONE
BRPI0512991A (en) use of a progestin, pharmaceutically useful kit adapted for daily oral administration, and method of contraception in a female of childbirth
NZ602698A (en) Parenteral pharmaceutical form which releases aromatase inhibitor and gestagens, for the treatment of endometriosis
PH12017502416A1 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
BRPI0516243C1 (en) use of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3b,17b-diol and 4-androsten-3,17-dione, use of said precursor in association with a selective estrogen receptor modulator for uterine and mammary gland protection against cancer, pharmaceutical composition and kit
BG108634A (en) Injectable compositions for the controlled delivery of pharmacologically active compound
BR122017008910A8 (en) COMPOSITIONS FORMULATED FOR INTRAMUSCULAR INJECTION AND USES OF A TESTOSTERONE ESTER
AR061289A1 (en) STABILIZED PHARMACEUTICAL COMPOSITIONS THAT INCLUDE FESOTERODINE
AR070379A1 (en) DRUG ADMINISTRATION SYSTEM WITH STABILIZING EFFECT
CL2011000044A1 (en) Use of an oral pharmaceutical composition comprising at least one opioid antagonist selected from naloxone, naltrexone, nalbuphine or its salts, additionally it may comprise at least one opioid agonist, such as oxycodone, morphine or others, for the treatment of urinary retention.
PE20100034A1 (en) DEVICE FOR IMPROVING A BLASTING METHOD
BRPI0912112B8 (en) pharmaceutical composition comprising compound having a2a adenosine receptor antagonistic activity useful in suppressing analgesic tolerance
BR112018010107A2 (en) pharmaceutical composition for the treatment or prevention of nash
BR112012015016A8 (en) PHARMACEUTICAL FORMULATION, ENTERAL PHARMACEUTICAL DOSAGE FORM AND USE OF A FORMULATION
AR072781A1 (en) COMPOSITIONS THAT INCLUDE CDB-4124 AND MALE CONTRACEPTION METHODS
AU2003251636A1 (en) COMPOSITION CONTAINING AN ANDROGENOUS 11Beta-HALOGEN STEROID AND A PROGESTATIONAL HORMONE, AND MALE CONTRACEPTIVE BASED ON SAID COMPOSITION
PE20160655A1 (en) COMPOUND FORMATION PROFARMACS
AR083820A1 (en) CLAMP FOR MOUNTING A FLUID SUPPLY DEVICE
WO2004091541A3 (en) Methods for the controlled delivery of pharmacologically active compounds
BR112013002280A2 (en) controlled release oral pharmaceutical compositions comprising blonansein

Legal Events

Date Code Title Description
FB Suspension of granting procedure